Lantern Pharma Inc. Other Nonoperating Income (Expense)
Lantern Pharma Inc. (LTRN) reported Other Nonoperating Income (Expense) of $14.93 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-14
- Lantern Pharma Inc. other nonoperating income (expense) for the quarter ending 2026-06-30 was $14.93K, a 92.76% decline year-over-year.
- Lantern Pharma Inc. other nonoperating income (expense) for the quarter ending 2026-03-31 was $33.92K, a 61.22% decline year-over-year.
- Lantern Pharma Inc. other nonoperating income (expense) for the quarter ending 2025-12-31 was $56.07K.
- Lantern Pharma Inc. other nonoperating income (expense) for the quarter ending 2025-09-30 was $71.46K, a 85.19% decline year-over-year.
- Lantern Pharma Inc. other nonoperating income (expense) for fiscal 2025 was $421.13K, a 39.22% decline from fiscal 2024.
- Lantern Pharma Inc. other nonoperating income (expense) for fiscal 2024 was $692.87K, a 39.78% decline from fiscal 2023.
- Lantern Pharma Inc. other nonoperating income (expense) for fiscal 2023 was $1.15M.
- Lantern Pharma Inc. other nonoperating income (expense) for fiscal 2022 was -$31.55K, a 119.65% decline from fiscal 2021.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.93K 10-Q · filed 2026-08-14 | $48.84K 10-Q · filed 2026-08-14 | $104.91K derived: sum of 3 quarters · filed 2026-08-14 | $176.37K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $33.92K 10-Q · filed 2026-05-15 | $89.99K derived: sum of 2 quarters · filed 2026-05-15 | $161.44K derived: sum of 3 quarters · filed 2026-05-15 | $367.58K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $56.07K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $127.53K derived: sum of 2 quarters · filed 2026-03-30 | $333.67K derived: sum of 3 quarters · filed 2026-08-14 | $421.13K 10-K · filed 2026-03-30 |
| 2025-09-30 | $71.46K 10-Q · filed 2025-11-12 | $277.60K derived: sum of 2 quarters · filed 2026-08-14 | $365.06K 10-Q · filed 2025-11-12 | $224.86K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $206.14K 10-Q · filed 2026-08-14 | $293.60K 10-Q · filed 2026-08-14 | $153.41K derived: sum of 3 quarters · filed 2026-08-14 | $635.93K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $87.46K 10-Q · filed 2026-05-15 | -$52.73K derived: sum of 2 quarters · filed 2026-05-15 | $429.79K derived: sum of 3 quarters · filed 2026-05-15 | $690.09K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$140.19K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $342.33K derived: sum of 2 quarters · filed 2026-03-30 | $602.63K derived: sum of 3 quarters · filed 2026-03-30 | $692.87K 10-K · filed 2026-03-30 |
| 2024-09-30 | $482.53K 10-Q · filed 2025-11-12 | $742.82K derived: sum of 2 quarters · filed 2025-11-12 | $833.06K 10-Q · filed 2025-11-12 | $1.26M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $260.30K 10-Q · filed 2025-08-13 | $350.54K 10-Q · filed 2025-08-13 | $774.61K derived: sum of 3 quarters · filed 2025-08-13 | $890.39K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $90.24K 10-Q · filed 2025-05-15 | $514.32K derived: sum of 2 quarters · filed 2025-05-15 | $630.09K derived: sum of 3 quarters · filed 2025-05-15 | $956.17K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $424.07K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $539.85K derived: sum of 2 quarters · filed 2025-03-27 | $865.93K derived: sum of 3 quarters · filed 2025-03-27 | $1.15M 10-K · filed 2025-03-27 |
| 2023-09-30 | $115.78K 10-Q · filed 2024-11-07 | $441.85K derived: sum of 2 quarters · filed 2024-11-07 | $726.57K 10-Q · filed 2024-11-07 | $1.10M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $326.08K 10-Q · filed 2024-08-08 | $610.80K 10-Q · filed 2024-08-08 | $981.29K derived: sum of 3 quarters · filed 2024-08-08 | $809.64K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $284.72K 10-Q · filed 2024-05-09 | $655.21K derived: sum of 2 quarters · filed 2024-05-09 | $483.56K derived: sum of 3 quarters · filed 2024-05-09 | $330.97K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $370.49K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $198.84K derived: sum of 2 quarters · filed 2024-03-18 | $46.25K derived: sum of 3 quarters · filed 2024-03-18 | -$31.55K 10-K · filed 2024-03-18 |
| 2022-09-30 | -$171.65K 10-Q · filed 2023-11-08 | -$324.24K derived: sum of 2 quarters · filed 2023-11-08 | -$402.04K 10-Q · filed 2023-11-08 | -$373.89K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$152.59K 10-Q · filed 2023-08-09 | -$230.39K 10-Q · filed 2023-08-09 | -$202.24K derived: sum of 3 quarters · filed 2023-08-09 | -$184.56K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$77.80K 10-Q · filed 2023-05-09 | -$49.65K derived: sum of 2 quarters · filed 2023-05-09 | -$31.97K derived: sum of 3 quarters · filed 2023-05-09 | $82.75K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $28.15K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $45.83K derived: sum of 2 quarters · filed 2023-03-20 | $160.55K derived: sum of 3 quarters · filed 2023-03-20 | $160.55K 10-K · filed 2023-03-20 |
| 2021-09-30 | $17.68K 10-Q · filed 2022-11-07 | $132.40K derived: sum of 2 quarters · filed 2022-11-07 | $132.40K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $114.72K 10-Q · filed 2022-08-08 | $114.72K 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |